As Amgen and Lilly Recommit, Puerto Rico Seeks To Regain Manufacturing Momentum

Why It Matters

The capital influx could re‑establish Puerto Rico as a competitive pharma hub, influencing reshoring trends and U.S. supply‑chain resilience. Success hinges on addressing infrastructure and workforce challenges that have eroded the island’s previous advantage.

Key Takeaways

• Amgen invests $650M, creating ~750 jobs
• Lilly commits $1.2B for oral GLP‑1 production
• Pharma employment fell from 29k (2004) to under 14k
• Automation may boost wages despite smaller workforce
• Unreliable power grid remains key investment hurdle

Pulse Analysis

The Trump administration’s reshoring push has revived interest in U.S. territories that can combine regulatory familiarity with lower‑cost operations. Puerto Rico, once a pharma hub thanks to a decade of generous tax credits, saw its manufacturing headcount plunge after those incentives expired in 2004. The recent $650 million expansion by Amgen in Juncos and Lilly’s $1.2 billion upgrade in Carolina signal a renewed confidence that the island can again serve as a cost‑effective production base, especially for high‑growth assets such as Lilly’s oral GLP‑1 candidate, orforglipron.

However, the island faces structural obstacles that could temper that optimism. The skilled labor pool that attracted the original wave is aging, and without a pipeline of new talent the workforce risk eroding. Automation at existing plants has helped maintain output with fewer employees, but it also shifts demand toward higher‑skill, higher‑pay roles. More pressing is the fragile electricity grid, still recovering from the 2017 hurricanes; frequent outages force manufacturers to rely on backup generators, adding operational complexity and cost. These factors keep investors wary despite the financial incentives on offer.

Policymakers are responding by bundling tax breaks with infrastructure commitments, aiming to present Puerto Rico as a resilient, strategically located gateway to both North and Latin American markets. The island’s U.S. legal framework simplifies compliance, while its ports and air cargo links reduce shipping times compared with offshore sites. If the grid upgrades and workforce development programs keep pace with automation, the new wave of capital could restore the island’s pharma manufacturing momentum and provide a template for other U.S. jurisdictions seeking to attract reshoring projects. The success of Amgen and Lilly will be a bellwether for the broader reshoring agenda.